Zydus Lifesciences, a global innovation-driven healthcare company, announced that its wholly-owned subsidiary, Zydus Lifesciences Global FZE, has signed an exclusive licensing and supply agreement with Viwit Pharmaceuticals (Viwit), an innovation-driven biopharmaceutical and healthcare company, for gadobutrol injection (generic version of GADAVISTTM) and gadoterate meglumine injection (generic version of DOTAREM®) in the United States.
Reliance Capital: Following a request by insolvent Reliance Capital's lenders, the National Company Law Appellate Tribunal (NCLAT) issued a notice to IndusInd International Holdings Ltd (IIHL). The lenders intend to lose ₹2,750 crore in equity if the Hinduja Group firm fails to follow the resolution plan. NCLAT has requested that IIHL answer within two weeks, with the matter slated for a hearing on September 30. Lenders are asking revisions to the July 23 NCLT judgement, which authorised IIHL to take over Reliance Capital for ₹9,861 crore, amid concerns about the plan's execution.
Mazagon Dock Shipbuilders has announced a final dividend of ₹12.11 per share for FY 2024, with September 19, 2024 as the record date for its AGM. This statement has sparked interest among shareholders and market analysts.